Studies of inhibitory immune checkpoints in TNBC have addressed mainly the PD-L1/PD-1 axis; they demonstrated the expression of PD-L1 and PD-1 by cancer cells and immune cells in the tumor and analyzed their connection to patient survival. Here, CD274 is linked to cancer.